Diverging visions on budget allocation and EU coordination in crisis management dominated the European Parliament’s joint ENVI-SANT meeting on 24 March 2026, where figures like Leire Pajín (S&D) and Aurelijus Veryga (ECR) clashed over the future shape of the Union Civil Protection Mechanism and health emergency preparedness. Pajín advocated a strict 40/40/20 split among civil protection, health, and a flexible component to ensure guaranteed funding and a comprehensive approach beyond response, while Veryga warned this rigidity risks reduced flexibility and duplication, urging clear limits on new hubs’ powers to preserve national competences.
The debate took place during a key joint ENVI-SANT committee session that also featured the European Commission presenting biotech regulations and ex vivo organ processing updates. MEPs examined a draft report linking civil protection with health preparedness amidst a backdrop of evolving crisis threats like war, climate damage, and pandemics.
Several concrete policy proposals emerged. Pajín and Veryga jointly proposed fixed earmarking to secure a dedicated funding envelope for health, civil protection, and flexible response, highlighting the risk of health funding disappearing in a broader pot. Michèla Matuella from DG ECHO cautioned against tight earmarking, stressing it could create rigid financial targets that hinder rapid response during unforeseen crises. Other speakers like Nicolae Ştefănuţă (Greens/EFA) called for even larger funds with sub-envelopes, showing support for increased Union powers in crisis flexibility.
Regarding coordination, Sirpa Pietikäinen (EPP) pushed for stronger EU powers and resources in medicines, stockpiling, and infrastructure citing Covid-19 lessons, while Laurent Castillo (PfE) and Aurelijus Veryga advocated preserving member states’ sovereignty especially in health alerts and biotech oversight to avoid bureaucratic duplication. The establishment of the Crisis Coordination Hub polarized opinions, with some members wanting clearer legal definitions and a robust operational role, and others warning against adding layers of administration.
On crisis strategy, the majority pushed for a shift from response-centred management toward anticipation, prevention, and recovery, involving local authorities, volunteers, and communication efforts tackling misinformation. Yet differences remained over the civil-military cooperation balance, with some urging stronger integration due to evolving threats, and others emphasizing the mechanism must remain fundamentally civil.
The biotech and organ processing updates sparked debate over innovation versus precaution. Adam Jarubas (EPP) and Jessica Polfjärd (EPP) highlighted streamlined risk-based authorisation to boost competitiveness, while criticism focused on the lack of impact assessments and possible risks from genetically modified micro-organisms. The organ processing amendment, targeting novel high-risk technologies, found broad support conditioned on strict safety oversight and respect for national competencies.
Stakeholders impacted range from EU producers in biotech and health sectors facing updated authorisation regimes and operational costs, to national authorities maintaining crisis decision powers and oversight roles. Consumers and patients could benefit from faster innovation and improved resilience, although there are concerns about bureaucratic complexity and funding inflexibility.
Looking ahead, with amendments due by April 9 and committee and plenary votes scheduled, expect continued negotiations to balance EU integration ambitions with national sovereignty, flexibility in crisis funds, and innovation with precaution safeguards. The final framework will shape how the EU responds to an intensifying crisis landscape and advances in health technologies.